AstraZeneca wird ab sofort auch für Ältere freigegeben nachrichten.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nachrichten.at Daily Mail and Mail on Sunday newspapers.
DER SPIEGEL
Suche öffnen
A Wartime Economy
Germany Needs to Give Vaccine Production a Shot in the Arm
It only took pharmaceuticals producer BioNTech a few months to set up a new vaccine factory in Germany. Berlin should use the case as an example in efforts to boost production of the medicines urgently needed to stop the COVID-19 pandemic.
German Health Minister Jens Spahn: A carrot-and-stick approach is needed.
Foto: dpa
Hope is arising between an environmentalist center and the mausoleum of German Nobel Prize laureate Emil von Behring. It can be found in handful of factory halls and administrative buildings on the outskirts of the German city of Marburg. Some of them are more than 100 years old, from the time when the factory was used to manufacture the first medicines used to treat tetanus. Now, the German biotech firm BioNTech is converting the site for the production of its COVID-19 vaccine. Beginning in March, the plant is expected to produce around 70 million doses a
Over 100 CMOs presently claim to offer manufacturing services for antibodies
The antibody contract manufacturing market is currently dominated by the presence of small and mid-sized companies, which represent 70% of the industry stakeholders. It is also worth highlighting that more than 55% of CMOs claim to have the capabilities to manufacture antibodies across all scales of operation (preclinical, clinical and commercial).
More than 90% service providers are focused on the production of monoclonal antibodies
However, players based in Asia are now increasingly focusing on the development of bispecific antibodies for therapeutic use. It worth highlighting that close to 20% of the CMOs engaged in this domain claim to offer manufacturing services for both bispecific antibodies and antibody fragments.